MedTrace Logo

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT05027867 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-08-16

No results posted yet for this study

Summary

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer.

This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms from Part 1.

Conditions

  • Small-cell Lung Cancer
  • Small Cell Lung Carcinoma
  • Small Cell Lung Cancer Extensive Stage
  • Small Cell Lung Cancer Recurrent

Interventions

DRUG

KRT-232

Administered by mouth

Sponsors & Collaborators

  • Kartos Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-06
Primary Completion
2022-08-26
Completion
2022-08-26
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Germany
  • Hungary
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05027867 on ClinicalTrials.gov